Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody

Immunotherapy targeting aggregated alpha-synuclein (αSYN) is a promising approach for the treatment of Parkinson’s disease. However, brain penetration of antibodies is hampered by their large size. Here, RmAbSynO2-scFv8D3, a modified bispecific antibody that targets aggregated αSYN and binds to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Roshanbin, Sahar, Julku, Ulrika, Xiong, Mengfei, Eriksson, Jonas, Masliah, Eliezer, Hultqvist, Greta, Bergström, Joakim, Ingelsson, Martin, Syvänen, Stina, Sehlin, Dag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318263/
https://www.ncbi.nlm.nih.gov/pubmed/35890306
http://dx.doi.org/10.3390/pharmaceutics14071412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318263/
https://www.ncbi.nlm.nih.gov/pubmed/35890306
http://dx.doi.org/10.3390/pharmaceutics14071412

Ejemplares similares